<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551888</url>
  </required_header>
  <id_info>
    <org_study_id>LAC-PK-01</org_study_id>
    <nct_id>NCT01551888</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 µg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 µg Via Foradil® Aerolizer® In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and
      tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall
      Inhaler and formoterol 12 μg via the Foradil® Aerolizer®, both administered twice daily for
      five days to patients with moderate to severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State</measure>
    <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)</time_frame>
    <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State</measure>
    <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)</time_frame>
    <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose</measure>
    <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose</time_frame>
    <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose</measure>
    <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose</time_frame>
    <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Aclidinium/formoterol 400/12μg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium/formoterol 400/12μg</intervention_name>
    <description>Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler</description>
    <arm_group_label>Aclidinium/formoterol 400/12μg FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®</description>
    <arm_group_label>Formoterol</arm_group_label>
    <other_name>Foradil® Aerolizer®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current or former cigarette smokers with a cigarette smoking history of at least 10
             pack-years

          -  A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined
             by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable
             airway obstruction.

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within three months
             prior to Screening

          -  Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the six weeks before Screening

          -  Patients with any clinically significant respiratory conditions other than COPD

          -  Clinical history that suggests that the patient has asthma as opposed to COPD

          -  Chronic use of oxygen therapy ≥ 15 hours/day

          -  Patients with clinically significant cardiovascular conditions

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics,
             beta-2 agonists, sympathomimetic amines, or inhaled medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site 001</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4102&amp;filename=LAC-PK-01_CSRredacted.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <results_first_submitted>October 4, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2016</results_first_posted>
  <disposition_first_submitted>August 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2012</disposition_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Airflow Obstruction, Chronic</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>Chronic Obstructive Airway Disease</keyword>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in a single center in the United States
First patient visit was in January 2012 and last patient visit was in March 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Aclidinium/formoterol 400 μg/12 μg FDC (via the Almirall inhaler) one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) for 1 day in Period 1 and, in Period 2, Formoterol 12 μg via the Foradil® Aerolizer®, one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) for 1 day</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Formoterol 12 μg via the Foradil® Aerolizer®, one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) for 1 day in Period 1 and, in Period 2, Aclidinium/formoterol 400 μg/12 μg FDC (via the Almirall inhaler) one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) for 1 day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>All patients participating in the crossover study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State</title>
        <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
        <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 μg</title>
            <description>Administered via Foradil® Aerolizer®</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg FDC</title>
            <description>Fixed dose combination (FDC) administered via Almirall inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State</title>
          <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
          <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.14" spread="27.8" lower_limit="0.08" upper_limit="2.00"/>
                    <measurement group_id="O2" value="85.15" spread="28.3" lower_limit="0.08" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State</title>
        <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
        <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 μg</title>
            <description>Administered via Foradil® Aerolizer®</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg FDC</title>
            <description>Fixed dose combination (FDC) administered via Almirall inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State</title>
          <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
          <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.90" spread="27.9" lower_limit="27.9"/>
                    <measurement group_id="O2" value="16.72" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose</title>
        <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
        <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 μg</title>
            <description>Administered via Foradil® Aerolizer®</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg FDC</title>
            <description>Fixed dose combination (FDC) administered via Almirall inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose</title>
          <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
          <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.63" spread="32.2" lower_limit="0.08" upper_limit="2.00"/>
                    <measurement group_id="O2" value="42.27" spread="31.3" lower_limit="0.08" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose</title>
        <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
        <time_frame>Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 μg</title>
            <description>Administered via Foradil® Aerolizer®</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/12 μg FDC</title>
            <description>Fixed dose combination (FDC) administered via Almirall inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose</title>
          <description>The standard deviation of the measure is expressed as the coefficient of variation (%)</description>
          <population>The pharmacokinetic (PK) analysis population included all patients who completed the study and had evaluable PK parameters</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.23" spread="39.9" lower_limit="27.9"/>
                    <measurement group_id="O2" value="9.55" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to study Day 17</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Fixed dose combination (FDC) administered via Almirall inhaler</description>
        </group>
        <group group_id="E2">
          <title>Formoterol 12 μg</title>
          <description>Administered via Foradil® Aerolizer®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the PI will be subject to mutual agreement between the PI and sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

